Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genzyme gets rights to Alnylam's RNAi candidates for ATTR; rights expanded in new deal

Executive Summary

RNAi therapeutics developer Alnylam Pharmaceuticals Inc. has granted Sanofi’s Genzyme Corp. exclusive rights to develop and sell two of its candidates targeting transthyretin (TTR; a protein normally produced by the liver) to treat transthyretin-mediated amyloidosis (ATTR). Sanofi’s rights cover Japan and other Asia-Pacific countries, including Korea, Taiwan, China, India, Australia, and New Zealand.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Concluded
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies